Early empiric therapy for invasive fungal infection in the ICU

Nosocomial fungal infection in the ICU

Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?

Prior analyses suggest that empiric fluconazole for ICU patients with sepsis is cost-effective. Using updated estimates of efficacy and cost, Zilberberg and colleagues compare the use of micafungin with that of fluconazole. The authors conclude that micafungin is an attractive alternative to fluconazole. This conclusion is driven by recent reduction in micafungin's cost and by better activity o...

Invasive Fungal Infection with Absidia Corymbifera in Immunocompetent Patient with Electrical Scalp Burn

Invasive fungal infection in burn injury is caused by inoculation of fungal spore from patient skin, respiratory tract or from care giver. The risk factors for acquiring fungal infection in burns include age of burns, total burn size, full thickness burns, inhalational injury, prolonged hospital stay, late surgical excision, open dressing, central venous catheters, antibiotics, steroid treatmen...

Fungal Infections in the ICU

ABBREVIATIONS IN THIS CHAPTER Anti-Mn Anti-mannan antibody AST Antifungal susceptibility testing ECIL European Conference on Infections in Leukemia ESCMID European Society of Clinical Microbiology and Infectious Diseases IA Invasive aspergillosis IC Invasive candidiasis IDSA Infectious Disease Society of America IFI Invasive fungal infection Mn Mannan antigen TDM Therapeutic drug monitoring 1. ...

Fungal infections in the ICU.

Pulmonologists and intensivists often care for patients at risk for infections caused by both Aspergillus and Candida. Infection with either can lead to severe life-threatening disease, particularly in immunosuppressed patients, with mortality rates for invasive fungal disease often exceeding 30%. For both organisms, multiple diagnostic challenges remain while newer diagnostic modalities are be...